Immunotherapy for melanoma (Q34573035)

3 August 2017

1 reference

title

Immunotherapy for melanoma. (English)

1 reference

3 August 2017

1 reference

5

Craig L Slingluff

1 reference

3 August 2017

Christina J Kim

1

1 reference

3 August 2017

Sophie Dessureault

series ordinal

2

1 reference

3 August 2017

Dimitry Gabrilovich

series ordinal

3

1 reference

3 August 2017

Douglas S Reintgen

series ordinal

4

1 reference

3 August 2017

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

9

1 reference

3 August 2017

22-30

1 reference

3 August 2017

1

1 reference

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

3 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Exposing the immunology of naked DNA vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

Inhibition of Tumour Growth by Administration of Killed Corynebacterium parvum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900104

10.1177/107327480200900104

21 January 2018

Identifiers

DOI

0 references

1 reference